Tome Biosciences is a genome-editing therapeutics company founded in 2021 and based in Watertown, Massachusetts. It develops programmable genomic integration (PGI) technology that pairs the site-specificity of CRISPR/Cas with integrase enzymes to insert genetic sequences of virtually any size into the genome without relying on double-strand DNA… - View it on GitHub